Michael Humes

President

Dr. Michael Humes is a global health epidemiologist and implementation scientist with more than two decades of experience across sub-Saharan Africa, including six years living in West Africa leading disease eradication efforts with The Carter Center. In senior roles with the President’s Malaria Initiative at the United States Agency for International Development, he helped redefine how countries use data to fight disease—scaling national surveillance systems, strengthening decision-making, and guiding multimillion-dollar malaria programs across multiple countries. His work sits at the intersection of epidemiology, data science, and implementation—turning complex health data into actionable strategies that improve outcomes at national and subnational levels.

As President of RegeneMed, Dr. Humes is focused on one goal: closing the gap between innovation and impact. He leads efforts to translate breakthrough medical technologies into scalable solutions for low- and middle-income countries—bringing advanced, life-saving devices into real-world clinical settings. His work ensures that innovation is not only effective, but accessible, affordable, and sustainable at scale—bringing next-generation care to the populations that need it most.

David Humes

Scientific Advisor / Board Member

Dr. H. David Humes, MD is a physician–scientist, nephrologist, and biomedical innovator whose work is redefining how critical illness is treated. A professor at the University of Michigan and founder of Innovative BioTherapies, he has spent decades advancing therapies that move beyond supportive care to directly target the biological drivers of organ failure.

He is the inventor of the Selective Cytopheretic Device (SCD), a first-in-class extracorporeal therapy that modulates dysregulated immune responses by selectively targeting activated immune cells. Designed for conditions such as sepsis and acute kidney injury, the SCD represents a paradigm shift—transforming dialysis into a precision immunomodulatory platform with the potential to improve survival and accelerate organ recovery.

At RegeneMed, Dr. Humes leads the scientific vision to translate these breakthroughs into scalable, low-cost solutions for global health—bringing advanced, life-saving care to the patients and settings where the need is greatest.

Stu Goldstein

Board Member

Dr. Stuart L. Goldstein, MD is a globally recognized leader in acute kidney injury (AKI) and pediatric critical care nephrology, serving as the Clark D. West Endowed Chair and Director of the Center for Acute Care Nephrology at Cincinnati Children’s Hospital Medical Center. Trained at Columbia University and Boston Children’s Hospital, he has fundamentally reshaped how AKI is identified and managed worldwide. As the developer of the pediatric-modified RIFLE (pRIFLE) criteria and leader of the landmark AWARE study published in the New England Journal of Medicine, Dr. Goldstein helped establish AKI as a critical, measurable driver of morbidity and mortality—laying the foundation for a new generation of targeted therapies and technologies.

Dr. Goldstein’s work now sits at the forefront of innovation—bridging discovery, clinical care, and device-enabled therapy to transform outcomes for critically ill children. As Founder of the Prospective Pediatric AKI Research Group, a global network of more than 60 centers, he has built the evidence base that enables precision approaches to AKI, including biomarker-guided care and advanced extracorporeal therapies. His leadership in international guideline development through KDIGO and national efforts to reduce nephrotoxic injury reflects a consistent focus on translating science into scalable solutions. With more than 400 publications and a career defined by firsts, Dr. Goldstein is helping drive a paradigm shift—from reactive kidney support to proactive, technology-enabled intervention—bringing life-saving innovations to the patients who need them most.

Anthony Batte

Board Member

Dr. Anthony Batte is a leading nephrologist and clinical researcher advancing kidney care in East Africa, with a focus on acute kidney injury (AKI), dialysis access, and critical care in resource-limited settings. Based in Uganda and affiliated with national referral and academic institutions, he has been at the forefront of efforts to expand renal services, strengthen clinical training, and improve outcomes for patients facing life-threatening kidney disease. His work spans frontline patient care, health system development, and research—addressing the growing burden of kidney disease in a region where access to dialysis and critical care remains limited.

Dr. Batte’s leadership is defined by a commitment to translating innovation into impact. He has played a key role in introducing and scaling dialysis services, advancing clinical research on AKI in infectious and critical illness, and building multidisciplinary collaborations to improve care delivery. As a clinician-scientist working at the intersection of global health and nephrology, he is helping shape a new model of kidney care in Africa—one that prioritizes access, sustainability, and locally driven solutions to save lives.